Abstract: The present disclosure provides non-invasive methods for determining the gender of an embryo during in vitro embryo culture.

Abstract: Disclosed are a method for analyzing an activation state of a signaling pathway in a cell or tissue through protein-protein interaction analysis, a method for selecting a tailored personal therapeutic agent and/or monitoring efficacy of a therapeutic agent using the analysis method, and a device for use therein.

Abstract: Methods and systems for identifying a protein within a sample are provided herein. A panel of antibodies are acquired, none of which are specific for a single protein or family of proteins. Additionally, the binding properties of the antibodies in the panel are determined. Further, the protein is iteratively exposed to a panel of antibodies. Additionally, a set of antibodies which bind the protein are determined. The identity of the protein is determined using one or more deconvolution methods based on the known binding properties of the antibodies to match the set of antibodies to a sequence of a protein.

Abstract: Methods for quantitation of fC1-INH from dried blood spot are provided herein. Such methods may comprise spotting and drying a blood sample on a support member, extracting protein from the dried blood sample and measuring the level of fC1-INH in the extracted proteins.

Abstract: The present invention relates to a method for diagnosing or pre-diagnosing a disease associated with podocyte foot process effacement in a subject or for determining the risk of a subject to develop a disease associated with podocyte foot process effacement, said method comprising the steps of a) determining the length of the slit diaphragm (ISD) formed by podocyte foot processes in a specific area A in a renal tissue sample of said subject by super resolution light microscopy; b) comparing the length of the slit diaphragm (ISD) formed by podocyte foot processes in a specific area A as determined in step (a) with the length of the slit diaphragm (ISD) formed by podocyte foot processes in a comparable specific area A in a renal tissue sample of a subject who at the time of the sampling showed no clinical symptoms of a disease associated with podocyte foot process effacement, wherein a deviation indicates a disease associated with podocyte foot process effacement.

Abstract: Methods and compositions for multiplexed protein-protein interaction profiling (e.g., immunoprofiling), based on nucleic acid tagging of polypeptides (e.g., by RNA display) are described. In some embodiments the described compositions and methods utilize a library of prey polypeptide targets linked to prey RNAs encoding them, and a population of bait polypeptides, e.g., a mixture of antibodies, that bind to one or more of the prey polypeptide targets and are used to isolate and identify the bound prey polypeptide targets by amplification of their associated prey RNAs and sequencing of the corresponding cDNAs. In other embodiments the prey polypeptide targets are linked to DNA Bar Codes, which serve as unique identifiers of the tagged polypeptide.

Abstract: According to a first aspect of the invention, there is provided a device for estimation of an ovulation date, comprising a camera, configured to obtain colour data of successive FSH test strips and a processor, configured to evaluate the colour data obtained by the camera. The processor is configured to determine a concentration value of each successive FSH test strip based on the data of the camera and to output a signal, if the processor determines that a first FSH downward trend of the FSH test strip values is occurring in the successive FSH test strips.

Abstract: The present invention relates to compositions and methods use in designing immunoassay controls. In various aspects, the invention provides synthetic peptides comprising the sequence CPRRPYIL (SEQ ID NO: 1) or an analog thereof; ELAGLGFAELQC (SEQ ID NO: 4) or an analog thereof; and CDWRKNIDAL (SEQ ID NO: 8) or an analog thereof; specific binding reagents that bind to a CPRRPYIL (SEQ ID NO: 1), ELAGLGFAELQC (SEQ ID NO: 4) or CDWRKNIDAL (SEQ ID NO: 8) peptide; methods of producing such reagents; and assays utilizing such reagents to provide assay controls signals that are unrelated to the measurement of the analyte or analytes of interest in that no reagents used in the analyte assay(s) contribute to the control signal.

Abstract: The present disclosure relates to assays and methods for the detection of renal inflammation by measuring the level of P2Y14 and/or UDP-glucose in a sample from a subject, such as a urine sample. The present disclosure also relates to methods for the treatment of renal inflammation by administering a P2Y14 inhibitor.

Abstract: Use of prostacyclin or an analogue thereof for treatment of a new medical indication in acute critically ill patients, in particular acute critically ill patients with systemic endothelial damage, a biomarker for identifying individuals that have a new medical indication, and a method for identifying a new medical indication.

Abstract: The invention generally provides improved compositions and methods for monitoring immune status of a subject. In particular, the invention provides methods for detecting BCMA in subjects to reliably monitor immune status of the subject.

Abstract: Methods are disclosed for identifying one or more proteins or polypeptides comprised by a sample. The methods comprise determining binding of each polypeptide with respect to each binding pool of a plurality of binding pools, wherein each binding pool comprises one or more probes which bind a structure comprised by a protein or polypeptide. In some aspects, polypeptides can be denatured and separated into individual polypeptide strands and immobilized on a solid support prior to determining binding of the binding pools. A protein, polypeptide or polypeptide strand can be identified by searching, in at least one database, for a protein or polypeptide sequence comprising binding pool targets either identical to or most similar to the binding pool targets comprised by the protein, polypeptide or polypeptide strand to be identified. Kits for identifying proteins, polypeptides and polypeptide strands are also disclosed.

Abstract: Described herein are methods for treating rheumatoid arthritis by determining whether a subject having rheumatoid arthritis will respond to an anti-TNF-alpha therapy based on the number of innate and adaptive immune cells in a sample from the subject prior to treatment.

Abstract: The invention relates to method of diagnosis a subject suffering from Adult-onset Still's disease and further to determine the disease course of the subject suffering from Adult-onset Still's disease.

Abstract: The present invention provides isolated immune cells, immune cell populations and compositions, as well as markers, marker signatures and molecular targets characterising the immune cells. The cell products, substances, compositions, markers, marker signatures, molecular targets, kits of parts and methods of the present invention provide for new ways to characterise, evaluate and modulate the immune system and immune responses.

Abstract: A method of diagnosing lung cancer in a subject-in-need thereof is provided. The method comprises: (a) providing a biological sample of the subject which comprises peripheral blood mononuclear cells (PBMCs); (b) in vitro contacting the PBMCs with a stimulant selected from the group consisting of the stimulants listed in Tables 3 and 4; and (c) measuring metabolic activity of the PBMCs having been contacted according to (b), wherein a statistically significant change in the metabolic activity of the PBMCs as compared to a control sample is indicative of lung cancer.

Abstract: The present invention relates to methods for identifying markers for systemic sclerosis (also scleroderma; SSc) and to the markers identified with the aid of this method, which can differentiate between SSc and other autoimmune diseases on the one hand and between different SSc subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control of SSc. The invention also relates to methods for screening and for validating active substances for use in SSc.

Abstract: The present disclosure relates to protein-polymer conjugates comprising an engineered binding oligomer protein and a polymer for detection of a ligand of interest, methods, compositions and kits thereof.

Abstract: The present invention relates to an in vitro method for identifying a skin wound in an individual as being a non-healing skin wound or healing skin wound, in vitro methods for monitoring the healing of a skin wound in an individual, methods for screening for compounds suitable for modulating skin wound healing, as well as kits related thereto.

Abstract: The present invention provides compositions exhibiting in vivo activity of fibrin in an in vitro setting, in vitro assays comprising such compositions, methods of producing such compositions, and methods of using such compositions and assays. The compositions of the invention include molecules with the biochemical properties of 1) high affinity binding to fibrin receptors and 2) activation of cell-signaling systems comparable to that observed in vivo by fibrin. The fibrin compositions of the invention are compatible both in biochemical assays and cell-based assays, and thus useful for in vitro assays for screening of test agents that modulate cell activation and/or signaling pathways mediated by fibrin or associated with fibrin activity.